Form 8-K - Current report:
SEC Accession No. 0000950170-25-014627
Filing Date
2025-02-05
Accepted
2025-02-05 17:00:10
Documents
12
Period of Report
2025-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20250130.htm   iXBRL 8-K 46875
2 EX-10.1 sabs-ex10_1.htm EX-10.1 158501
  Complete submission text file 0000950170-25-014627.txt   379230

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20250130.xsd EX-101.SCH 47154
14 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20250130_htm.xml XML 6620
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 25594178
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)